This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Another Great Depression Imminent or Is it Just a Myth?
by Urmimala Biswas
Asian countries have already shown clear signs of major economic recession.
Thermo Fisher Expands Lab Plastic Making for Coronavirus Support
by Zacks Equity Research
Thermo Fisher (TMO) consumables already support critical COVID-19 work and include sample collection vials and lab essentials.
Quest Diagnostics (DGX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Quest Diagnostics (DGX) closed the most recent trading day at $113.59, moving +0.77% from the previous trading session.
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Quidel, QIAGEN and Thermo Fisher Scientific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Quidel, QIAGEN and Thermo Fisher Scientific
3 Med Info Stocks to Improve Portfolio Health Amid Coronavirus Woes
by Urmimala Biswas
Postponement of elective surgeries leading to lower product bookings cloud Zacks-Medical Info Systems industry prospects. However, coronavirus-led demand for contactless services should aid the space. TXG, MDRX, NXGN should be the forerunners.
Coronavirus Test Makers With Scope to Maximize Investor Benefits
by Urmimala Biswas
The surge in new coronavirus infections broadens the scope for antigen and antibody tests.
Quest Diagnostics (DGX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Quest Diagnostics (DGX) closed at $107.05 in the latest trading session, marking a -0.33% move from the prior day.
Quest Diagnostics (DGX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Quest Diagnostics (DGX) closed the most recent trading day at $110.69, moving +0.95% from the previous trading session.
3 Top Outpatient and Home Healthcare Stocks to Watch Out For
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, rising dependence on telehealth and AI's dominant role should drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, USPH and PNTG are well positioned to gain from the prospects.
The Zacks Analyst Blog Highlights: Abbott Lab, Quidel, Becton, Dickinson and Company, Hologic and Quest Diagnostics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Lab, Quidel, Becton, Dickinson and Company, Hologic and Quest Diagnostics
Price War in Coronavirus Test Space to Intensify Thanks to Abbott
by Urmimala Biswas
Most rapid antigen tests in the United States require an additional system, which is making the procedures more costly and complex.
Why Is Quest Diagnostics (DGX) Down 7.7% Since Last Earnings Report?
by Zacks Equity Research
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Anthem, Quest Tie up to Improve Healthcare Across the US
by Zacks Equity Research
Anthem (ANTM) teams up with Quest in order to improve health outcomes to consumers with the help of their innovative solutions.
Is Quest Diagnostics (DGX) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks.com featured highlights include: Quest Diagnostics, eBay, Cisco Systems, Cigna and AbbVie
by Zacks Equity Research
Zacks.com featured highlights include: Quest Diagnostics, eBay, Cisco Systems, Cigna and AbbVie
5 Coronavirus-Proof GARP Stocks to Pick on Discounted PEG
by Urmimala Biswas
A lower PEG ratio, preferably less than 1, is always better for GARP investors.
Here's Why You Should Add AMN Healthcare to Your Portfolio
by Zacks Equity Research
Investor confidence is high in AMN Healthcare (AMN) stock, thanks to solid prospects.
Quest Diagnostics' (DGX) Q2 Earnings Beat, Volume Declines
by Zacks Equity Research
Following the guidance withdrawal last quarter, Quest Diagnostics (DGX) provides its full-year projection alongside Q2 earnings release.
Quest Diagnostics (DGX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 0.71% and 0.16%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Has Quest Diagnostics (DGX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (DGX) Outperforming Other Medical Stocks This Year?
Here's Why You Should Add QIAGEN (QGEN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
Why Earnings Season Could Be Great for Quest Diagnostics (DGX)
by Zacks Equity Research
Quest Diagnostics (DGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
PerkinElmer (PKI) Launches DBS Test for Coronavirus Diagnosis
by Zacks Equity Research
PerkinElmer (PKI) unveils DBS-based test, being marketed as a CE-IVD test, while intending to apply for its FDA EUA soon.
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, Lithia Motors, Quest Diagnostics, Pool and Boston Beer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, Lithia Motors, Quest Diagnostics, Pool and Boston Beer
4 Top Stocks to Buy Ahead of Earnings Release
by Zacks Equity Research
Healthcare, consumer staples and retail sectors could be ideal investments right now, keeping in mind the growing demand for their products.